EA201300215A1 - Лечение митохондриальных болезней нафтохинонами - Google Patents

Лечение митохондриальных болезней нафтохинонами

Info

Publication number
EA201300215A1
EA201300215A1 EA201300215A EA201300215A EA201300215A1 EA 201300215 A1 EA201300215 A1 EA 201300215A1 EA 201300215 A EA201300215 A EA 201300215A EA 201300215 A EA201300215 A EA 201300215A EA 201300215 A1 EA201300215 A1 EA 201300215A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
mitochondrial diseases
nafthochinones
treatment
mitochondrial
Prior art date
Application number
EA201300215A
Other languages
English (en)
Inventor
Орион Д. Янковски
Эндрю В. Хинман
Гай М. Миллер
Original Assignee
Эдисон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эдисон Фармасьютикалз, Инк. filed Critical Эдисон Фармасьютикалз, Инк.
Publication of EA201300215A1 publication Critical patent/EA201300215A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Раскрываются способы лечения, предотвращения или подавления симптомов, связанных с митохондриальными болезнями, такими как атаксия Фридрейха (FRDA), атрофия зрительного нерва (LHON), доминантная оптическая атрофия (DOA); митохондриальная миопатия, энцефалопатия, лактацидоз, инсультоподобные эпизоды (MELAS), синдром Лея или синдром Кирнса-Сейра (KSS) с помощью соединений формулы I. Кроме того, раскрываются способы модулирования, нормализации или увеличения энергетических биомаркеров, а также соединения, пригодные в таких способах.
EA201300215A 2010-08-06 2011-08-04 Лечение митохондриальных болезней нафтохинонами EA201300215A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40104410P 2010-08-06 2010-08-06
PCT/US2011/046630 WO2012019029A2 (en) 2010-08-06 2011-08-04 Treatment of mitochondrial diseases with naphthoquinones

Publications (1)

Publication Number Publication Date
EA201300215A1 true EA201300215A1 (ru) 2013-07-30

Family

ID=45560075

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300215A EA201300215A1 (ru) 2010-08-06 2011-08-04 Лечение митохондриальных болезней нафтохинонами

Country Status (10)

Country Link
US (1) US20130345312A1 (ru)
EP (1) EP2600857A4 (ru)
JP (2) JP6045494B2 (ru)
AU (1) AU2011285619B2 (ru)
BR (1) BR112013002877A2 (ru)
CA (1) CA2807507A1 (ru)
EA (1) EA201300215A1 (ru)
MX (1) MX2013001469A (ru)
SG (1) SG187744A1 (ru)
WO (1) WO2012019029A2 (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032544A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Treatment of mitochondrial diseases
EP2471530B1 (en) 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
EA038941B1 (ru) 2007-11-06 2021-11-12 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
US8952071B2 (en) 2008-01-08 2015-02-10 Edison Pharmaceuticals, Inc. (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
CA2717734A1 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
US8716486B2 (en) 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
CA2736250C (en) 2008-09-10 2016-12-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
EP2963006B1 (en) 2008-10-28 2018-10-17 BioElectron Technology Corporation Composition containing alpha-tocotrienol quinone,and intermediates thereof
PL2424495T3 (pl) 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
WO2013013078A1 (en) 2011-07-19 2013-01-24 Edison Pharmeceuticals, Inc. Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
HUE033757T2 (en) 2012-07-12 2017-12-28 Khondrion Ip B V Chromanil derivatives for the treatment of mitochondrial disease
WO2014039862A1 (en) * 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
HUE046924T2 (hu) 2013-03-01 2020-03-30 Stealth Biotherapeutics Corp Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra
EP3673913A1 (en) * 2013-03-01 2020-07-01 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial disease
JP2016515526A (ja) 2013-03-15 2016-05-30 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2015103577A1 (en) * 2014-01-06 2015-07-09 Stealth Peptides International, Inc. Methods and compositions for preventing or treating dominant optic atrophy
ES2912585T3 (es) 2014-12-16 2022-05-26 Ptc Therapeutics Inc Formas polimórficas y amorfas de la (R)-2-hidroxi-2-metil-4-(2,4,5-trimetil-3,6-dioxociclohexa-1,4-dienil)butanamida
US10815211B2 (en) 2015-10-08 2020-10-27 Khondrion Ip B.V. Compounds for treating mitochondrial disease
US10745371B2 (en) 2015-12-16 2020-08-18 Ptc Therapeutics, Inc. Methods for enriching alpha-tocotrienol from mixed tocol compositions
CN113024369A (zh) 2015-12-17 2021-06-25 Ptc医疗公司 用于治疗氧化应急障碍的化合物
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
CA3058033A1 (en) 2017-04-05 2018-10-11 Khondrion Ip B.V. Treatment of mitochondrial diseases
AU2018255492B2 (en) 2017-04-21 2021-10-28 University Of Tasmania Therapeutic compounds and methods
WO2020028222A1 (en) * 2018-07-29 2020-02-06 Musc Foundation For Research Development Compounds for the treatment of neurological or mitochondrial diseases
DK3866772T3 (da) 2018-10-17 2024-01-15 Ptc Therapeutics Inc 2,3,5-trimethyl-6-nonylcyclohexa-2,5-dien-1,4-dion til undertrykkelse og behandling af alpha-synucleinopathier, tauopathier og andre lidelser
CA3127654A1 (en) 2019-01-25 2020-07-30 Universitat Autonoma De Barcelona Cannabidiol and/or derivatives thereof for use in the treatment of mitochondrial diseases
KR20220078644A (ko) 2019-10-04 2022-06-10 스텔스 바이오테라퓨틱스 인코포레이티드 미토콘드리아 질환 치료를 위한 바티퀴논의 퀴논-, 히드로퀴논- 및 나프토퀴논-유사체
IT202100006065A1 (it) * 2021-03-15 2022-09-15 Univ Degli Studi Padova Composto per l’uso nel metodo di trattamento delle malattie mitocondriali da disfunzione dei complessi i, ii, iii della catena respiratoria
KR20240032997A (ko) 2021-07-08 2024-03-12 피티씨 테라퓨틱스, 인크. 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온을 포함하는 약제학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117326D0 (en) * 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
JP2003226639A (ja) * 2002-01-31 2003-08-12 Hisamitsu Pharmaceut Co Inc 神経成長因子活性増強剤としてのビタミンｋ類を含む医薬組成物およびその使用
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
EP2471530B1 (en) * 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
RU2318500C2 (ru) * 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
JP5374162B2 (ja) * 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
KR20080047959A (ko) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물
CA2717734A1 (en) * 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
CA2736250C (en) * 2008-09-10 2016-12-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
WO2011082355A1 (en) * 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
EP2601168A4 (en) * 2010-08-06 2013-12-04 Ampere Life Sciences Inc TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K
WO2012170773A1 (en) * 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones

Also Published As

Publication number Publication date
JP2013541502A (ja) 2013-11-14
US20130345312A1 (en) 2013-12-26
CA2807507A1 (en) 2012-02-09
JP6045494B2 (ja) 2016-12-14
EP2600857A2 (en) 2013-06-12
WO2012019029A3 (en) 2013-08-15
MX2013001469A (es) 2013-05-14
JP2016041772A (ja) 2016-03-31
WO2012019029A2 (en) 2012-02-09
EP2600857A4 (en) 2014-06-11
AU2011285619B2 (en) 2016-12-01
BR112013002877A2 (pt) 2016-05-31
AU2011285619A1 (en) 2013-03-07
SG187744A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
EA201300215A1 (ru) Лечение митохондриальных болезней нафтохинонами
EA201001119A1 (ru) Производные (гет)арил-п-хинона для лечения митохондриальных болезней
CY1122480T1 (el) Μεθυλικη βαρδοξολονη για τη θεραπεια παχυσαρκιας
EP2601168A4 (en) TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
CY1117200T1 (el) Παραγωγα βενζυλαμινης ως αναστολεις καλλικρεϊνης πλασματος
CU20120101A7 (es) Derivados de triazolopirazinas sustituidas como inhibidores del receptor c-met o hgf para tratar el cáncer
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
DOP2016000017A (es) Nuevos compuestos tricíclicos
CY1117706T1 (el) Παραγωγα οξαζολινης και ισοξαζολινης ως ρυθμιστες crac
EA201101668A1 (ru) Редокс-активные терапевтические средства для лечения митохондриальных нарушений
CU24414B1 (es) Lactamas n-(heteroarilo sustituido) fusionadas útiles en el tratamiento del crecimiento celular anormal
CO6321273A2 (es) N-fenil -y - lactamas subtituidas las cuales son agonistas ep2 para ser usados como agentes terapeuticos para el tratamiento de glaucoma, sindrome del intestino irritable y calvicie
BRPI1016257B8 (pt) composições compreendendo finafloxacina para tratamento de infecções óticas
EA201790800A1 (ru) Замещенные производные бензотиофенила в качестве агонистов gpr40 для лечения диабета ii типа
CU24402B1 (es) 2,6 purinas di-sustituidas útiles en el tratamiento de trastornos proliferativos tales como cáncer
ECSP11011245A (es) Novedosos herbicidas
UA107562C2 (uk) Спосіб лікування псоріазу
DOP2009000177A (es) Uso de derivados de acido de piranona sustituidos para el tratamiento del sindrome metabolico
BR112017011883A2 (pt) composição de organosiloxano com alto índice de refração e aplicações contendo a mesma
BR112014011641A2 (pt) composto; composição; uso de um composto; método para tratar pelo menos uma doença, distúrbio ou condição selecionada de obesidade, sobrepeso ou distribuição de gordura anormal e condições ou doenças associadas com os mesmos em um sujeito em necessidade do mesmo; método para remodelar tecido adiposo branco para tecido adiposo tipo marrom em um sujeito; método para tratar uma doença, distúrbio ou condição associada com ou se beneficiando da remodelação de tecido adiposo branco para tecido adiposo tipo marrom em um sujeito; e método para reduzir o tecido adiposo branco (wat) em um sujeito em necessidade do mesmo
PE20170914A1 (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa
DOP2012000260A (es) Uso de nuevos inhibidores de pan–cdk para tratar tumores
UY33496A (es) Derivados heterociclicos fusionados como moduladores s1p
UY33495A (es) Derivados de bisaril (tio)morfolina como moduladores s1p